Q4 2025 Moderna Inc Earnings Call Transcript
Key Points
- Moderna Inc (MRNA) reported a significant reduction in operating expenses, down 30% year-over-year, demonstrating strong cost discipline.
- The company ended 2025 with a robust cash and investments balance of $8.1 billion, exceeding their initial guidance.
- Moderna Inc (MRNA) has made substantial progress in its oncology pipeline, with multiple late-stage studies fully enrolled, including those for adjuvant melanoma and muscle invasive bladder cancer.
- The company announced strategic agreements with Mexico and Taiwan, enhancing its international market presence and revenue potential.
- Moderna Inc (MRNA) expects up to 10% revenue growth in 2026, driven by international markets and new product launches.
- The company faced a net loss of $2.8 billion for the year 2025, highlighting ongoing financial challenges.
- Moderna Inc (MRNA) received a refusal to file letter from the FDA for its flu vaccine mRNA 1,010, creating regulatory uncertainty.
- The US COVID market demand declined year-over-year, impacting domestic revenue generation.
- There is uncertainty regarding the timing and approval of the flu-COVID combination vaccine in the US, pending further discussions with the FDA.
- The company anticipates potential declines in COVID vaccination rates, which could affect future revenue streams.
Thank you, Kevin. Good morning, everyone, and thank you for joining us on today's call to discuss Moderna's 4th quarter 2025 financial results and business updates. You can access the press release issued this morning as well as the slides that we'll be reviewing by going to the investors section of our website.
On today's call are Stefan Bonsell, our Chief Executive Officer, Stephen Hoag, our President, and Jamie Mack, our Chief Financial Officer.
Before we begin, please note that this conference call will include forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1,995. Please see slide 2 of the accompanying presentation and our SEC filings for important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements. With that, I will turn the call over to Stefan.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
